FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has further expanded its European business of High Intensity Focused Ultrasound (“HIFU”) using the Sonablate® 500 (“SB500”) for prostate cancer treatment through a distribution agreement with Takai Hospital Supply Co., Ltd. (“THSI”) (www.thsinternational.com) to market the SB500 in Turkey, Greece and Cyprus.
